The Impact of Novel Anti-Diabetic Medications on CV Outcomes: A New Therapeutic Horizon for Diabetic and Non-Diabetic Cardiac Patients

Keyphrases

• Diabetic 100%
• Non-diabetic 100%
• New Therapeutics 100%
• Major Adverse Cardiovascular Events 100%
• Antidiabetic Drugs 100%
• Cardiovascular Outcomes 100%
• Cardiac Patients 100%
• Diabetes Mellites 100%
• Patients with Diabetes 66%
• Antidiabetic 66%
• A1 Receptor 33%
• Number of Patients 33%
• Receptor Agonist 33%
• High Risk 33%
• All-cause Mortality 33%
• Cardiovascular Disease 33%
• Heart Failure 33%
• Current Guidelines 33%
• Cardiovascular Effects 33%
• Revascularization 33%
• Lipid-lowering Medications 33%
• Antiplatelet Agents 33%
• Glucagon-like 33%
• Atherosclerotic Cardiovascular Disease (ASCVD) 33%
• Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i) 33%
• Event Outcomes 33%
• Antidiabetic Effect 33%

Medicine and Dentistry

• Cardiovascular System 100%
• Cardiovascular Disease 100%
• Anti-Diabetic Medication 100%
• Patient with Diabetes 50%
• Antidiabetic Agent 50%
• Diabetes Mellitus 25%
• Diabetes 25%
• All Cause Mortality 25%
• Clinician 25%
• Congestive Heart Failure 25%
• Revascularization 25%
• Antiplatelet Drug 25%
• Sodium Glucose Cotransporter 2 Inhibitor 25%
• Glucagon-Like Peptide-1 Agonist 25%
• Antidiabetic Activity 25%
• Arteriosclerotic Heart Disease 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Anti-Diabetic Medication 100%
• Cardiovascular Disease 100%
• Antidiabetic Agent 75%
• Diabetes Mellitus 25%
• All Cause Mortality 25%
• Congestive Heart Failure 25%
• Coronary Artery Atherosclerosis 25%
• Antithrombocytic Agent 25%
• Glucagon Like Peptide 1 Receptor Agonist 25%
• Sodium Glucose Cotransporter 2 Inhibitor 25%